Magnetic Resonance Imaging Assessment of Small Bowel Motility

University College London (UCL) logo

University College London (UCL)

Status

Unknown

Conditions

Motility Disorder of Intestine

Study type

Observational

Funder types

Other

Identifiers

NCT02754869
11/0307

Details and patient eligibility

About

This project involves the development, validation and application of a novel test using MRI to assess gastrointestinal motility a vital process that mixes the contents of our digestive tract. This process frequently becomes deranged in conditions like chronic constipation, Parkinson's and Crohn's disease.

Full description

Gastrointestinal motility refers to the contractile actions in the gut that serve to mix our food and propel it through out digestive tract. Although known to be involved in a range of conditions like chronic constipation, Parkinson's and Crohn's disease, investigator have never had effective tests with which to study the process. Advances in medical imaging technologies now make it possible to both see and quantify this process non-invasively using MRI. In this study the investigator first of all validate that our MRI based analysis is robust and valid, producing predictable results against range of known stimuli. The investigator then apply the technique to a cohort of participants with Chronic Intestinal Pseudo-Obstruction. These participants are known to have hypo-motile small bowels and demonstration with our MRI technique would serve as further validation. The investigator also investigate two cohorts of people with and without gastrointestinal diseases to better understand how the technique may work in the clinical setting. By the end of this project The investigator will have generated robust initial evidence to validate our MRI technique and clinical data to inform use further research.

Enrollment

172 estimated patients

Sex

All

Ages

16+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

ELIGIBILITY CRITERIA - CONTROL SUBJECTS DRUG STUDY:

  • Adult (>16 years)
  • Body Mass Index within the range of (18---25)

ELIGIBILITY CRITERIA - DYSMOTILITY SUBJECTS DRUG STUDY:

  • Adult patients (>16 years) 2
  • Dysmotility diagnosis including CIPO
  • Body Mass Index within the range of (18---35)

ELIGIBILITY CRITERIA - REFERENCE RANGE STUDY (NORMAL PARTICIPANTS):

• Adult (>16 years)

ELIGIBILITY CRITERIA - REFERENCE RANGE STUDY (DYSMOTILITY/IBS):

  • Adult patients (>16 years)
  • Dysmotility, CIPO or IBS diagnosis

ELIGIBILITY CRITERIA - DYSMOTILITY REVERSIBILITY STUDY:

  • Adult (>16 years)
  • Known small bowel Crohn's disease starting anti TNF alpha medication or undergoing endoscopic small bowel stricture dilatation.

Exclusion criteria

EXCLUSION CRITERIA - CONTROL SUBJECTS DRUG STUDY:

  • Any contraindications to MRI scans (e.g. Implanted cardiac pacemaker, defibrillator device)
  • Inability to give consent
  • Treatment for any chronic illness
  • Use of laxatives, anti---diarrhoeals or any drugs affecting GI motility (including NSAIDs) prohibited within one week of the scan.
  • Cardiac symptoms (palpitations).
  • Abnormal GI symptoms (eg. constipation, diarrhea, bloating, pain) as per the Rome III criteria for Irritable Bowel Syndrome
  • Pregnancy
  • Asthma EXCLUSION CRITERIA - DYSMOTILITY SUBJECTS DRUG STUDY: (18) Version 4.1
  • Any contraindications to MRI scans (e.g. Implanted cardiac pacemaker, defibrillator device)
  • Inability to give consent
  • Use of laxatives, anti---diarrhoeals or any drugs affecting GI motility (including NSAIDs) prohibited within 1---3 days (or according to half life of drug) of the scan.
  • Cardiac symptoms (palpitations).
  • Pregnancy
  • Asthma

EXCLUSION CRITERIA - REFERENCE RANGE STUDY (NORMAL PARTICIPANTS):

  • Any contraindications to MRI scans (e.g. Implanted cardiac pacemaker, defibrillator device)
  • Inability to give consent 3. Treatment for any chronic illness
  • Use of laxatives, anti---diarrhoeals or any drugs affecting GI motility (including NSAIDs) prohibited within 1---3 days (or according to half life of drug) of the scan.

EXCLUSION CRITERIA - REFERENCE RANGE STUDY (DYSMOTILITY/IBS):

  • Any contraindications to MRI scans (e.g. Implanted cardiac pacemaker, defibrillator device)
  • Inability to give consent
  • Use of laxatives, anti---diarrhoeals or any drugs affecting GI motility (including NSAIDs) prohibited within 1---3 days (or according to half life of drug) of the scan.

EXCLUSION CRITERIA - DYSMOTILITY REVERSIBILITY STUDY:

  • Any contraindications to MRI scans (e.g. Implanted cardiac pacemaker, defibrillator device)
  • Inability to give consent
  • Use of laxatives, anti---diarrhoeals or any drugs affecting GI motility (including NSAIDs) prohibited within 1---3 days (or according to half life of drug) of the scan.

Trial design

172 participants in 4 patient groups

Control Subject-Drug Study
Description:
The first part of this investigation is an interventional blinded cross over study with two dosing dates spread at least one week apart. Each volunteer will receive baseline scans before drug/placebo which will be used to assess intra---patient variation over the two study dates after which the drug or saline placebo will be administered with each volunteer acting as their own control to assess software ability to quantify changes in bowel motility.
Dysmotility Subjects-Drug Study
Description:
The second component of this study will be exactly the same for the participants with dysmotility except the time to repeat scan will be reduced with a follow up time aimed at around 1---3 days reducing patient time off medication
Reference Range Study
Description:
The third component of this study will assess basal small bowel motility in larger numbers of healthy controls, dysmotility subjects and irritable bowel syndrome to establish reference ranges to inform future clinical investigations and guide clinical decision making using global motility scoring. Each scan will last around 20 minutes and will not involve follow up or use of pharmaceutical agents.
Desmotility Reversibility Study
Description:
The fourth component of the study will assess small bowel motility in a cohort of Crohns disease patients will small bowel disease before and 11---16 weeks after starting anti TNF alpha therapy, or undergoing endoscopic dilatation of a small bowel stricture. Each scan will last around 45 minutes

Trial contacts and locations

1

Loading...

Central trial contact

Alex Menys

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems